Insider Transactions in Q3 2022 at Novo Cure LTD (NVCR)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 29
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-10.57%
|
$520,058
$77.35 P/Share
|
|
Sep 22
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
6,754
-9.56%
|
$520,058
$77.0 P/Share
|
|
Sep 15
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
12,271
-7.7%
|
$1,079,848
$88.65 P/Share
|
|
Sep 15
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
5,517
+6.24%
|
$38,619
$7.15 P/Share
|
|
Sep 09
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,863
-2.17%
|
$163,944
$88.0 P/Share
|
|
Sep 06
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,384
-1.58%
|
$107,952
$78.57 P/Share
|
|
Sep 02
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
269
-0.32%
|
$21,251
$79.04 P/Share
|
|
Sep 02
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
296
-0.18%
|
$23,384
$79.04 P/Share
|
|
Sep 02
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
885
-1.21%
|
$69,915
$79.04 P/Share
|
|
Sep 02
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
718
-1.28%
|
$56,722
$79.04 P/Share
|
|
Sep 02
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
584
-0.66%
|
$46,136
$79.04 P/Share
|
|
Sep 01
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
14,212
-1.24%
|
$1,094,324
$77.43 P/Share
|
|
Aug 03
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,959
-8.73%
|
$429,048
$72.54 P/Share
|
|
Aug 02
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
414
-0.4%
|
$28,566
$69.66 P/Share
|
|
Aug 02
2022
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
837
-0.15%
|
$57,753
$69.66 P/Share
|
|
Aug 02
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,122
+8.86%
|
$498,540
$70.2 P/Share
|
|
Aug 02
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
437
-1.25%
|
$30,153
$69.66 P/Share
|
|
Jul 05
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
281
+0.56%
|
$16,579
$59.08 P/Share
|
|
Jul 05
2022
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
312
+0.37%
|
$18,408
$59.08 P/Share
|
|
Jul 05
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
312
+0.3%
|
$18,408
$59.08 P/Share
|
|
Jul 05
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
218
+0.13%
|
$12,862
$59.08 P/Share
|
|
Jul 05
2022
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
276
+1.99%
|
$16,284
$59.08 P/Share
|
|
Jul 05
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
251
+0.38%
|
$14,809
$59.08 P/Share
|
|
Jul 05
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213
+0.38%
|
$12,567
$59.08 P/Share
|
|
Jul 05
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
222
+0.63%
|
$13,098
$59.08 P/Share
|
|
Jul 05
2022
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
144
+0.84%
|
$8,496
$59.08 P/Share
|